UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported):
February 27, 2020
 
INNOVATION PHARMACEUTICALS INC.
(Exact Name of Registrant as Specified in Charter)
  
Nevada
 
001-37357
 
30-0565645
(State or Other Jurisdiction
 
(Commission
 
(IRS Employer
of Incorporation)
File Number)
 
Identification No.)
 
301 Edgewater Place - Suite 100

Wakefield, Massachusetts
 
01880
(Address of Principal Executive Offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code:
(978) 921-4125
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐   
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered under Section 12(b) of the Exchange Act: none
 
Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company   
 
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
   
 
 
 
 
 
Item 7.01. Regulation FD Disclosure
 
On February 27, 2020, Innovation Pharmaceuticals Inc. issued a press release titled, Innovation Pharmaceuticals to Ship Brilacidin to U.S. Regional Biocontainment Laboratory for Research Against Coronavirus COVID-19.
 
A copy of the press release is furnished herewith as Exhibit 99.1. The information in this Current Report on Form 8-K under Item 7.01, including the accompanying press release, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by reference to such filing.
 
Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits.
 
Exhibit No.
Description
 
   
 
 2
 
 
  
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
INNOVATION PHARMACEUTICALS INC.
       
Dated: February 27, 2020 By:
/s/ Leo Ehrlich
 
Name:
Leo Ehrlich  
  Title: Chief Executive Officer  
    
 
 3
 
Innovation Pharmaceuticals (PK) (USOTC:IPIX)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Innovation Pharmaceuticals (PK) Charts.
Innovation Pharmaceuticals (PK) (USOTC:IPIX)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Innovation Pharmaceuticals (PK) Charts.